Dune Medical Recieved EU Approval for MarginProbe
21 March, 2013
Cancer re-operation rate was reduced by 56% when the MarginProbe System was employed. The unique technology behind is based on RF Spectroscopy
MarginProbe identify the electromagnetic “signature” of a cancerous tissue
Dune Medical Devices has received CE approval for its next generation MarginProbe System console. The MarginProbe System Type 1.2 is a portable compact of the MarginProbe System console for the operating theaters.
The MarginProbe System delivers real-time cancer detection in the OR for immediate assessment of cancer on the margin of excised tissue. In a randomized study of 300 breast cancer patients in Israel, the re-operation rate was reduced by 56% when the MarginProbe System was employed Vs. the standard of care.
The unique technology behind MarginProbe is based on RF spectroscopy, long used in industries such as semiconductor, pharmaceutical, aerospace and fuel cell. When tissue becomes cancerous, the effect is on all the components of the tissue, including both cells and the extracellular medium. These effects, which are the hallmark of cancer, include changes in the polarization of cell membranes; the volume of the nucleus and the rapid copying of DNA; the growth of new blood vessels; and a decrease in the connectivity from one cell to another.
Each of these changes influences the way that tissue responds to an applied electric field, leading to a unique electromagnetic signature. By subjecting tissue to an electric field, and then measuring the tissue response to that field, the system can identify the electromagnetic “signature” of the cancerous tissue, and outline its borders.
This is important for the treatment success: following a lumpectomy, surgeons will send the removed tissue to the pathology lab where it is analyzed for cancer on the margin. This is critical information because if there is cancer present on the edges of the removed tissue, there is a possibility that cancer still remains in the breast. Once a tissue sample is sent to pathology for analysis, it can take approximately one week or more to receive the lab results that determine if the patient must undergo a repeat surgery.
Inability to know if all cancerous cells have been removed from the breast during the initial lumpectomy procedure results in repeat surgery rates ranging from 30 to 60%. Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony and is backed by Apax Partners since 2004. It has offices in the U.S., Israel, Germany and Switzerland. The company received CE marking in 2006 and is is currently in clinical trials at 18 centers in the US.